Editas medicine stock price.

Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. …3 Nov 2023 ... ... Editas Medicine's financial status. The company holds a market cap of 684.13M USD, reflecting its size in terms of market value. The price ...Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ...Price as of December 1, 2023, 4:00 p.m. ET ... This fact has led to a stomach-churning level of volatility among stocks tied to CRISPR and related forms of gene ... Editas …

EDITAS MEDICINE DL-,0001 share price in real-time (A2AC4K / US28106W1036), charts and analyses, news, key data, turnovers, company data.Editas Medicine closed an underwritten offering of 4,025,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. This included 525,000 shares issued upon exercise in full by the underwriters of their option to purchase additional shares.Editas Medicine's (NASDAQ: EDIT) lead candidate, EDIT-101, is a gene-editing therapy that targets a rare genetic disease called Leber congenital amaurosis 10, which leads to progressive blindness ...

For example, Editas Medicine (EDIT 11.37%) and Exact Sciences (EXAS 7.07%) fell by 66.5% and 36.4% respectively over the course of 2022. Since the change in the calendar year, Editas stock has ...

View Editas Medicine, Inc EDIT investment & stock information. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Oct 2, 2023 · Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. By Alex Carchidi – Oct 2, 2023 at 10:00AM ... Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET. Jun 20, 2023 · On June 15, Editas Medicine ( EDIT 3.66%) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use ...

Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 27.54% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $9.06 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $13.94 and as low as $6.08. Year to date, Editas ...

Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Editas Medicine Inc’s Stock Price as of Market Close. As of May 16, 2023, 4:00 PM CST, Editas Medicine Inc’s stock price was $9.55. Editas Medicine Inc is down 4.6% from its previous closing price of $10.01. During the last market session, Editas Medicine Inc’s stock traded between $9.58 and $10.51. Currently, there are 68.92 …The stock option provides for the purchase of up to 123,350 shares of Editas Medicine common stock at a price of $8.00 per share, the closing price per share of Editas Medicine common stock as ...Beaten-down healthcare stocks Editas Medicine (EDIT-1.21%) and Bluebird Bio (BLUE 0.52%) could be two of the market's best short-squeeze candidates right now. Both companies have become top short ...Stock Quote & Chart. Data Provided by Refinitiv. Minimum 15 minutes delayed.Nov 24, 2023 · What is the target price for Editas Medicine (EDIT) stock? A. The latest price target for . Editas Medicine (NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023. Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. …Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.

Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksCAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ...

Nov 24, 2023 · Editas Medicine Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 10.97. Positive dynamics for Editas Medicine shares will prevail with possible volatility of 3.528%. Pessimistic target level: 10.80. Optimistic target level: 11.19. Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET ... Editas Medicine (EDIT 2.28%) is on the cutting edge of CRISPR. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR ...

Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET ... Editas Medicine (EDIT 2.28%) is on the cutting edge of CRISPR. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR ...Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00.Editas Medicine Inc (NASDAQ: EDIT) has agreed to license its proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies to Shoreline Biosciences.The average price target on the stock implies a 67% gain over the next 12 months. ... The past month has been a great one for Editas Medicine (EDIT 0.86%), but the stock is still down about 89% ...According to 5 analyst offering 12-month price targets in the last 3 months, Editas Medicine has an average price target of $15.4 with a high of $19.00 and a low of $12.00.

View Editas Medicine, Inc EDIT investment & stock information. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Nov 24, 2023 · What is the target price for Editas Medicine (EDIT) stock? A. The latest price target for . Editas Medicine (NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023. For example, Editas Medicine (EDIT 11.37%) and Exact Sciences (EXAS 7.07%) fell by 66.5% and 36.4% respectively over the course of 2022. Since the change in the calendar year, Editas stock has ...Our indicative theme on Gene Editing Stocks - which includes names such as CRISPR Therapeutics, Editas Medicine, and others - has returned about 230% over the past 2 years, compared to the broader ...Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT). Editas Medicine, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: EDIT | Nasdaq ... RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating ... Stock Editas Medicine, Inc. - Nasdaq . Consensus Editas Medicine, Inc. CATEGORIES. Indexes; …Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Editas Medicine, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: EDIT | Nasdaq ... RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating ... Stock Editas Medicine, Inc. - Nasdaq . Consensus Editas Medicine, Inc. CATEGORIES. Indexes; …Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT). This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...With all that said, here are the most exciting genomic stocks that you won’t want to miss out on. NTLA Intellia Therapeutics $37.75 BEAM Beam Therapeutics $30.71 EDIT Editas Medicine $8.16.Instagram:https://instagram. nuclear energy stocksthomas peter rothgrant cadronei need a thousand dollars now View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Jun 6, 2021 · For Editas Medicine stock forecast for 2031, 12 predictions are offered for each month of 2031 with average Editas Medicine stock forecast of $8.2, a high forecast of $8.21, and a low forecast of $8.19. The average Editas Medicine stock forecast 2031 represents a 4.21% increase from the last price of $7.86999988555908. leggmasonotcmkts mcoa According to 5 analyst offering 12-month price targets in the last 3 months, Editas Medicine has an average price target of $15.4 with a high of $19.00 and a low of $12.00.Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get... klip etf dividend history What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ... Get Editas Medicine Inc (EDIT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsStifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. ... Shares of Editas Medicine (EDIT 2.28%) ...